BRIEF-Piramal Pharma Says US FDA Inspection At Turbhe Facility
ReutersFeb 18, 2025 11:33 AM
Feb 18 (Reuters) - Piramal Pharma Ltd PIRM.NS:
US FDA INSPECTION AT PIRAMAL PHARMA'S FACILITY LOCATED AT TURBHE
ON CONCLUSION OF INSPECTION, A FORM-483 WAS ISSUED WITH 6 OBSERVATIONS
Source text: ID:nBSE410CGn
Further company coverage: PIRM.NS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
Global Crypto Treasury Boom: Which Companies and Tokens Are Becoming Investor Favorites?
A Crypto Treasury refers to a company allocating idle or raised capital to purchase cryptocurrencies, integrating them into its balance sheet as reserve assets or yield-generating tools.TradingKey
Wed, Jul 30
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
